Drug Profile
Research programme: nanotherapeutics - PendreaBio
Alternative Names: Chemotherapeutic NanoJackets; Doxorubicin NanoJackets; MDs - PendreaBio; Molecular Dots - PendreaBio; NanoJacketed chemotherapeutics; NanoJacketed doxorubicinLatest Information Update: 14 Jan 2022
Price :
$50
*
At a glance
- Originator Keystone Nano
- Developer The Pennsylvania State University
- Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Small molecules
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Oct 2016 No development reported - Preclinical for Breast cancer treatment in USA (Parenteral)